Deep Multi-omic Blood-Based Biomarker Discovery in People with Smoking History Demonstrates High Early Detection of NSCLC

Lung cancer is the leading cause of cancer-related deaths worldwide, with 236,740 new cases and 118,830 deaths estimated in the United States in 2022, with smoking as a major driver of risk. Liquid biopsies based on peripheral blood sampling hold great promise to reduce lung cancer morbidity and mortality by enabling early detection to downstage disease at initial diagnosis, theragnostic identification and efficacy monitoring to maximize benefit and minimize harm of specific therapeutic interventions, and detection of residual disease.